Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | JUN | P05412 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CHKA | P35790 | 1/20 | 0.32 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.32 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27807873 | 0.77 | SIRT6 (0.41) | JUNNFKB1NFKB2RELASIRT6 | |
| SCHEMBL18443080 | 0.76 | SIRT6 (0.34) | JUNNFKB1NFKB2RELASIRT6 | |
| SCHEMBL18442595 | 0.76 | JUN (0.31) | JUNNFKB1NFKB2RELASIRT6 | |
| SCHEMBL30185867 | 0.76 | SIRT6 (0.34) | JUNNFKB1NFKB2RELASIRT6 | |
| SCHEMBL9924589 | 0.75 | SIRT6 (0.35) | SIRT6 | |
| SCHEMBL29770810 | 0.75 | SIRT6 (0.35) | SIRT6 | |
| SCHEMBL17164929 | 0.74 | SIRT6 (0.41) | JUNNFKB1NFKB2RELASIRT6 | |
| SCHEMBL933680 | 0.74 | — | — | |
| SCHEMBL16635101 | 0.72 | AAK1 (0.39) | TRPV4 | |
| SCHEMBL17162215 | 0.72 | BACE1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | claimed |
| EP-4688155-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | Bial-Portela & CA, S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | claimed |
| WO-2025023852-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | claimed |
| CN-107840828-B | Synthesis method of 2-chloro-5-trifluoromethylpyrazine | 金凯(辽宁)化工有限公司 | 2020-11-03 | — | — | CN | claimed |
| CN-108067233-A | Improve foam nickel-base catalyst of sludge hot hydrolysis efficiency and preparation method thereof | 北京达源环保科技有限公司 | 2018-05-25 | — | — | CN | claimed |
| CN-107879583-A | Sludge pyrohydrolysis and anaerobic digestion integrated treatment process system | 北京达源环保科技有限公司 | 2018-04-06 | — | — | CN | claimed |
| CN-107840828-A | A kind of synthetic method of the trifluoromethyl pyrazine of 2 chlorine 5 | 金凯(辽宁)化工有限公司 | 2018-03-27 | — | — | CN | claimed |
| CN-101792420-A | Preparation of halogenated n-heteroaromatic polyhalogen derivatives | SALTIGO GMBH | 2010-08-04 | — | — | CN | claimed |
| WO-2026106499-A1 | OREXIN RECEPTOR ANTAGONISTS: 2-AZABICYCLIC COMPOUNDS | BIAL - PORTELA & CA., S.A. (PT) | 2026-05-21 | — | — | WO | disclosed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-5493024-A | 1,2-DIARYL-2-PROPEN-1-ONE CHEMICAL INTERMEDIATE COMPOUND | DOWELANCO (US) | 1996-02-20 | — | — | US | disclosed |
| US-5324837-A | 3,4-disubstituted-4,5-dihydro-1H-pyrazoles and a method of preparation | DOWELANCO (US) | 1994-06-28 | — | — | US | disclosed |
| US-5250532-A | Moths. termites | DOWELANCO (US) | 1993-10-05 | — | — | US | disclosed |
| CN-1067426-A | 3,4, N-three replaces-4,5-dihydro-1 h-pyrazole-1-methane amide and they application as sterilant | DOWELANCO (US) | 1992-12-30 | — | — | CN | disclosed |
| EP-0508469-A1 | 3,4,N-Trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides | DOWELANCO (US) | 1992-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137680-A1 | NOVEL COMPOUNDS | CCR1, CCR4, CCR3 | TRPV4 1034/4885JUN 1634/4885NFKB1 293/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | TRPV4 4429/4885JUN 963/4885NFKB1 4100/4885 |
| US-20260085060-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | TRPV4 1029/4885JUN 4224/4885NFKB1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.